

Structural Basis for Autoactivation of Human Mst2 Kinase and Its Regulation by RASSF5

Lisheng Ni,¹ Sheng Li,^{1,4} Jianzhong Yu,³ Jungki Min,^{1,5} Chad A. Brautigam,² Diana R. Tomchick,² Duoqia Pan,³ and Xuelian Luo^{1,*}

¹Department of Pharmacology

²Department of Biophysics

The University of Texas Southwestern Medical Center, 6001 Forest Park Road, Dallas, TX 75390, USA

³Department of Molecular Biology and Genetics, Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

⁴Present address: Biologics Department, Shanghai ChemPartner Co. Ltd., Shanghai 201203, China

⁵Present address: Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, USA

*Correspondence: xuelian.luo@utsouthwestern.edu

<http://dx.doi.org/10.1016/j.str.2013.07.008>

SUMMARY

The tumor-suppressive Hippo pathway controls tissue homeostasis through balancing cell proliferation and apoptosis. Activation of the kinases Mst1 and Mst2 (Mst1/2) is a key upstream event in this pathway and remains poorly understood. Mst1/2 and their critical regulators RASSFs contain Salvador/RASSF1A/Hippo (SARAH) domains that can homo- and heterodimerize. Here, we report the crystal structures of human Mst2 alone and bound to RASSF5. Mst2 undergoes activation through transautophosphorylation at its activation loop, which requires SARAH-mediated homodimerization. RASSF5 disrupts Mst2 homodimer and blocks Mst2 autoactivation. Binding of RASSF5 to already activated Mst2, however, does not inhibit its kinase activity. Thus, RASSF5 can act as an inhibitor or a potential positive regulator of Mst2, depending on whether it binds to Mst2 before or after activation-loop phosphorylation. We propose that these temporally sensitive functions of RASSFs enable the Hippo pathway to respond to and integrate diverse cellular signals.

INTRODUCTION

The Hippo pathway controls organ size and tissue homeostasis through coordinately regulating cell growth, proliferation, and death. This tumor-suppressive pathway was first characterized in *Drosophila* through genetic screens for mutations that caused tissue overgrowth and was later shown to be conserved in mammals (Badouel et al., 2009; Edgar, 2006; Halder and Johnson, 2011; Harvey and Tapon, 2007; Harvey et al., 2013; Pan, 2010; Staley and Irvine, 2012; Zhao et al., 2010a). The core components of the mammalian Hippo pathway include the Ste20 family kinases Mst1 and Mst2 (Mst1/2), the scaffolding protein Salva-

dor (Sav1), the NDR family kinases Lats1 and Lats2 (Lats1/2), and the adaptor protein Mob1. They form a central kinase cascade to transduce signals from cell-surface receptors (Avruch et al., 2012; Hergovich, 2012).

In the canonical Hippo kinase cascade, Mst1/2, in complex with Sav1, phosphorylate and activate the Lats1/2-Mob1 complexes, which then phosphorylate the transcriptional coactivator Yes-associated protein (YAP), a major downstream target of the Hippo pathway (Dong et al., 2007; Hao et al., 2008; Hong and Guan, 2012; Huang et al., 2005; Zhao et al., 2007). Lats1/2-mediated phosphorylation inhibits YAP in two ways. Phosphorylation of YAP at S127 by Lats1/2 creates a docking site for 14-3-3 proteins. Binding of 14-3-3 causes the cytoplasmic sequestration and inactivation of YAP (Dong et al., 2007; Hao et al., 2008; Zhao et al., 2007). Phosphorylation of YAP at S381 by Lats1/2 promotes its ubiquitination and degradation (Zhao et al., 2010b).

When the Hippo pathway is turned off, YAP is dephosphorylated and translocates into the nucleus. Although YAP does not contain a DNA-binding domain, it binds to the TEAD family of transcription factors (which contains a sequence-specific DNA-binding domain) to form a functional hybrid transcription factor (Luo, 2010; Sudol et al., 2012; Zhao et al., 2008). The YAP-TEAD hybrid then activates the transcription of Hippo-responsive genes that promote cell growth and proliferation and inhibit apoptosis.

Tremendous progress has been made toward the dissection of the molecular circuitry of the Hippo pathway and toward the understanding of the pathophysiology of this pathway in multiple organisms. By contrast, mechanistic and structural studies in this area have lagged behind. In particular, the activation mechanisms of the core Mst1/2-Lats1/2 kinase cascade remain elusive. The upstream kinases Mst1/2 contain an N-terminal kinase domain and a C-terminal SARAH (Salvador/RASSF1A/Hippo) domain (Figure 1A). Mst1 and Mst2 can each form a constitutive homodimer through the SARAH domain, and kinase activation requires autophosphorylation of the activation loop (T183 for Mst1 and T180 for Mst2) (Avruch et al., 2012; Creasy et al., 1996). The Mst1/2 regulators, the Sav1 and RASSF proteins, also contain SARAH domains (Figure 1A). The Mst1/2




Figure 1. Structural Basis for Mst2 Autoactivation

(A) Domain organization of human Mst2 and RASSF5. RA, Ras-association domain. Residue numbers for the boundaries of corresponding domains are labeled.

(B) Structure superposition of the kinase-active Mst1 kinase domain (PDB code: 3COM) and the kinase-inactive Mst2 kinase domain (this study). Mst1 is indicated in gray, and Mst2 is indicated in green. The activation loop from Mst1 is indicated in orange with residues phospho-T177 and phospho-T183 shown in sticks. The activation loop from Mst2 is indicated in magenta.

(C) Close-up view of the activation loops from Mst1 and Mst2. The color scheme is the same as in (B). R148 and phospho-T183 of Mst1 are shown as sticks. T180 in Mst2 is shown as sticks and labeled in italics. All structural figures were generated with PyMOL (<http://www.pymol.org>).

(D) SARAH-mediated homodimerization is critical for Mst2 auto-activation at T180. The kinetic profiles of T180 autophosphorylation of full-length Mst2 (0.5 μ M) and Mst2 kinase domain (KD) (0.5 μ M) were shown. The relative α -Mst2 P-T180 intensities were normalized against Mst2 reaction at 60 min (100%).

(E) Mst2 kinase domain alone is inefficient in T180 autophosphorylation. The kinetic profiles of T180 autophosphorylation of Mst2 kinase domain (KD) at two different concentrations (2 μ M and 0.5 μ M) are shown. The relative α -Mst2 P-T180 intensities were normalized against Mst2^{KD} without λ phosphatase treatment (100%). Data are representative of at least two independent experiments. See also Figure S1.

SARAH domain can form a heterodimer with RASSF SARAH (Hwang et al., 2007) and a heterotetramer with Sav1 SARAH (data not shown). RASSF binding and Sav1 binding to Mst1/2 are mutually exclusive. How RASSFs and Sav1 regulate Mst1/2 activation by forming different SARAH-domain-dependent complexes is not understood.

RASSFs are important tumor suppressors (Avruch et al., 2009; Richter et al., 2009). Their expression is frequently silenced in human cancers through promoter methylation, and reintroduced expression of RASSF1A or RASSF5 inhibits human tumor cell growth (Aoyama et al., 2004). In addition, RASSF1A knockout mice have increased spontaneous and chemical-induced tumor susceptibility (Tommasi et al., 2005). The roles of RASSFs in the tumor-suppressive Hippo pathway are far from clear, however. In *Drosophila*, the only RASSF protein (dRASSF) forms a heterodimer with Hippo through SARAH heterodimerization and prevents Salvador from binding to Hippo, thereby inhibiting the Hippo pathway (Polesello et al., 2006). Paradoxically, dRASSF also antagonizes Ras signaling and, in this capacity, has tumor-suppressive function. In mammals, RASSF1, RASSF5, and RASSF6 block Mst1/2 autophosphorylation and activation,

possibly through SARAH heterodimerization (Ikeda et al., 2009; Khokhlatchev et al., 2002; Praskova et al., 2004). On the other hand, RASSFs can positively regulate Mst1/2 (Guo et al., 2007; Oh et al., 2006). For example, coexpression of RASSFs with Ras enhances the Mst1 kinase activity. RASSF1A disrupts the interaction between proto-oncogene Raf1 and Mst2 and enhances the Mst2-Lats1 interaction to promote apoptosis through the Hippo pathway (Matallanas et al., 2007). RASSF2 associates with Mst1/2 through its SARAH domain to stabilize and activate Mst1/2 (Cooper et al., 2009; Song et al., 2010). Thus, in both *Drosophila* and mammals, RASSFs appear to have both negative and positive regulatory functions in the Hippo pathway.

Here, we report the crystal structures of the human Mst2 kinase domain and Mst2 in complex with the SARAH domain of RASSF5. SARAH-mediated homodimerization of Mst2 is critical for its transautophosphorylation and activation. RASSF5 disrupts this dimer interface and blocks Mst2 autoactivation. It is interesting that binding of RASSF5 to Mst2 that has already undergone autoactivation does not inhibit the kinase activity of Mst2 toward the downstream substrate Mob1. This lack of inhibition of active Mst2 might permit RASSF5 to have a positive regulatory role in the Hippo signaling. Thus, the order of RASSF5 binding and activation-loop phosphorylation

Table 1. X-Ray Crystallography Data Collection and Refinement Statistics for Mst2^{KD} and Mst2-RASSF5

Statistics	Crystal		
	Mst2 ^{KD}	Mst2-RASSF5	Mst2-RASSF5 SeMet
Data Collection			
Space group	C2	C2	C2
Energy (eV)	12,683.7	12,683.7	12,683.7
Resolution range (Å)	46.0–2.42 (2.46–2.42)	47.1–3.05 (3.10–3.05)	45.6–3.55 (3.61–3.55)
Unique reflections	83,949 (3,787)	65,746 (2,170)	31,896 (1,617)
Multiplicity	4.5 (3.5)	4.1 (3.8)	4.5 (4.4)
Data completeness (%)	99.5 (91.2)	99.1 (90.7)	99.9 (100.0)
R _{merge} (%) ^a	5.2 (53.7)	10.9 (76.2)	14.9 (76.5)
I/σ(I)	27.4 (1.7)	14.4 (1.6)	11.7 (1.7)
Wilson B value (Å ²)	56.4	80.2	82.7
	Mst2 ^{KD}	Mst2-RASSF5	
Refinement Statistics			
Resolution range (Å)	29.8–2.42 (2.48–2.42)		29.6–3.05 (3.11–3.05)
Number of reflections R _{work} /R _{free}	83,826/1,997 (5,491/134)		50,374/2,524 (2,308/124)
Data completeness (%)	99.5 (94.0)		98.6 (88.9)
Atoms (non-H protein/nucleotide/solvent/)	13,179/NA/279		12,609/124/NA
R _{work} (%)	19.3 (26.4)		19.9 (29.9)
R _{free} (%)	23.1 (32.4)		24.4 (36.9)
rmsd bond length (Å)	0.002		0.006
rmsd bond angle (°)	0.64		0.61
Mean B value (Å ²) (protein/nucleotide/solvent)	79.7/NA/60.0		135.8/142.9/NA
Ramachandran plot (%) (favored/additional/disallowed) ^b	96.4/3.4/0.2		95.4/4.3/0.3
Maximum likelihood coordinate error	0.30		0.29
Missing residues, by chain	A: 16–17, 36–37, 309–313; B: 16–18, 36–38, 165–170, 306–313; C: 16–17, 308–313; D: 16–25, 48–51, 58–68, 92–95, 165–182, 309–313; E: 16–17, 35–38, 59–63, 174–179, 303–313; F: 16–17, 166–182, 309–313		A: 9–15, 428–436, 489–491; B: 9, 428–442, 489–491; C: 9–11, 33–39, 428–436, 491; D: 9–10, 428–454, 490–491; E: 366; F: 366–369, 399–413; H: 406–413

Data for the outermost shell are given in parentheses. NA, not applicable; SeMet, selenomethionine.

^aR_{merge} = 100 Σ_i Σ_j |I_{h,i} − ⟨I_h⟩| / Σ_i Σ_j I_{h,i}, where the outer sum (h) is over the unique reflections and the inner sum (i) is over the set of independent observations of each unique reflection.

^bAs defined by the validation suite MolProbity.

determines whether RASSF5 acts as an inhibitor of Mst2. We speculate that the temporal regulation of the binding between Mst1/2 and RASSFs might enable RASSFs to perform dual functions in the Hippo pathway.

RESULTS AND DISCUSSION

Structure of the Mst2 Kinase Domain in Its Inactive State

The crystal structure of the activated Mst1 kinase domain (Mst1^{KD}), with two residues (T177 and T183) of its activation loop phosphorylated, has recently been determined in a structural genomics effort. The structure of the Mst1/2 kinase domain in its inactive, unphosphorylated state is unknown, however. We thus created a catalytically inactive mutant of the human Mst2 kinase domain (Mst2^{KD/D146N}), with its catalytic residue D146 mutated to an asparagine and determined its crystal structure (Figure 1B). The structure was solved by molecular replacement

(MR) with the Mst1^{KD} structure (Protein Data Bank [PDB] code 3COM) as the search model (Table 1). The kinase domain of Mst2 in our structure adopts a canonical kinase fold, without Mg²⁺-ATP bound to the active site located at the interface of the N and C lobes. The salt bridge between K56 of strand β3 and E70 of helix αC (which is critical for ATP binding) is not present in our unphosphorylated Mst2 structure. The overall structures of the Mst1 and Mst2 kinase domains are very similar, with a root-mean-square deviation (rmsd) of 1.0 Å excluding the activation loop, as expected from their 90% amino acid identity (Figure 1B). Comparison of the inactive and active states of Mst1/2, however, reveals phosphorylation-dependent conformational changes in its activation loop. The phosphorylated activation loop in the active Mst1 adopts an extended conformation suitable for substrate binding (Figure 1C). As in other kinases that require activation-loop phosphorylation for activation, the phosphoresidue in the activation loop (T183 in Mst1) makes favorable




Figure 2. The Conventional Model for Mst2 Transautophosphorylation

(A) T180 phosphorylation is critical for the Mst2 kinase activity. In vitro kinase assay of Mst2 kinase domain (KD) and its mutants using Mob1 as substrate and in the presence of γ -³²P-ATP. The reaction mixtures were separated on SDS-PAGE and analyzed by a phosphorimager (top) and Coomassie blue staining (bottom). Each reaction was done in duplicate.

(B) The phosphorylation-defective mutant T180A of Mst2 kinase domain (KD) phosphorylates kinase-inactive Mst2^{KD/D146N} more efficiently than it phosphorylates Mob1. The kinetic profiles of Mst2^{KD} or Mst2^{KD/T180A} were shown on the left. An enlarged view of the boxed region on the left graph is shown on the right. The ³²P intensities were normalized against Mst2^{KD} WT reactions at 60 min (100%) with substrates Mst2^{KD/D146N} and Mob1, respectively. Data are representative of at least two independent experiments.

See also Figure S2.

electrostatic interactions with the arginine (R148 in Mst1) in the catalytic loop. By contrast, the unphosphorylated activation loop in the inactive Mst2 structure folds into an α helix that blocks the active site of the kinase. Phosphorylation-mediated conformational rearrangement of its activation loop thus underlies Mst1/2 activation.

Mst2 Undergoes Activation through Transautophosphorylation of T180

The full-length Mst1/2 or their kinase domains purified from bacteria are phosphorylated at their respective activation loops, indicating that Mst1/2 can undergo autophosphorylation-dependent activation and does not require upstream kinases for activation. To monitor the kinetics of Mst2 activation in vitro, we treated purified, active Mst2 with λ phosphatase to remove its activation-loop phosphorylation, incubated the dephosphorylated Mst2 with cold ATP for 1 hr, and blotted Mst2 with an antibody against phospho-T180 Mst2 (α -Mst2 pT180). The full-length Mst2 indeed underwent efficient autophosphorylation at T180 in vitro (Figure 1D). By contrast, the Mst2 kinase domain alone was inefficient in T180 autophosphorylation, even at a higher concentration (Figure 1E). Consistent with previous findings, the full-length Mst2 eluted as a dimer during gel filtration, whereas the kinase domain of Mst2 migrated predominantly as a monomer (Figure S1 available online). Our results suggest that the C-terminal SARAH domain of Mst2 is critical for the homodimerization of Mst2 and for T180 autophosphorylation and Mst2 activation.

In the conventional model of the initial activation of kinases that undergo activation-loop transautophosphorylation, the activation loop of an unphosphorylated kinase molecule transiently adopts an active conformation and phosphorylates the activation loop of a neighboring kinase molecule to fully activate

it (Pirrucello et al., 2006). We tested whether Mst2 used a similar transautophosphorylation mechanism. Mst2 undergoes autophosphorylation on two residues: T174 and T180 in its activation loop. The T174A mutant of the Mst2 kinase domain (Mst2^{KD/T174A}) is fully active, whereas the T180A mutant is largely inactive toward a key downstream substrate Mob1 (Figure 2A). Thus, T180 phosphorylation, but not T174 phosphorylation, is critical for Mst2 activation. Mst2^{KD} phosphorylated the catalytically inactive Mst2^{KD/D146N}, indicating that Mst2 could undergo transautophosphorylation (Figures 2B and S2). It is interesting that, despite not being able to permanently reach the phosphorylated active state, the phosphorylation-deficient Mst2^{KD/T180A} mutant phosphorylated Mst2^{KD/D146N} to some extent and, in fact, more efficiently than it phosphorylated Mob1 (Figure 2B). Thus, the unphosphorylated activation loop of Mst2 might transiently adopt a conformation that is more amenable for transautophosphorylation than for phosphorylation of a bona fide substrate. Our results support the conventional model for Mst2 transautoactivation.

Distinct Residues Mediate Mst2 Autophosphorylation and Phosphorylation of Its Downstream Substrates

Despite being predominantly a monomer on gel filtration columns (Figure S1B), the Mst2 kinase domain exists as a homodimer in the crystal (Figure 3A). The Mst2 kinase domain in isolation indeed formed a weak dimer in solution, with a dissociation constant, K_D , of 36 μ M as measured by analytical ultracentrifugation (Figures 3B and S3; Table S1). To test whether the weak dimerization of the Mst2 kinase domain involved the interface observed in the crystal, we introduced mutations at this interface and measured the dimerization affinity. Unexpectedly, none of the mutations appreciably altered the dimerization of the Mst2 kinase domain in its active or inactive states (Table S1). Therefore, this interface might not mediate the dimerization seen in solution.




Figure 3. Identification of Key Residues Required for Mst2 Autophosphorylation

(A) Ribbon drawing of the Mst2 crystallographic dimer. Monomer A is colored green, and the activation loop is colored magenta. Monomer B is colored cyan, and the activation loop is colored wheat. I193 is shown in sticks.

(B) Sedimentation velocity analytical ultracentrifugation analysis of Mst2^{KD/D146N}. Three c(s) size distributions are shown, normalized by the total amount of signal in each. The distributions represent three separate sedimentation velocity experiments performed at differing concentrations. Populations of monomer (2.9 S) and dimer (4.1 S) change as a function of concentration, a hallmark of a monomer-dimer equilibrium. This part was made using GUSI (<http://biophysics.swmed.edu/MBR/software.html>). S, sedimentation coefficient.

(C) In vitro kinase assay of the interface mutants of Mst2 kinase domain based on the structure shown in (A). Mst2^{KD/D146N} was used as the substrate. The autoradiography of ³²P incorporation is shown at the top. The ³²P intensities of each mutant normalized against WT Mst2^{KD} (100%) were quantified and are indicated below the autoradiography. The western blot of phospho-T180 Mst2 is shown in the middle. The Coomassie blue staining of Mst2^{KD/D146N} is shown at the bottom.

(D) In vitro kinase assay of the interface mutants of Mst2 kinase domain using Mob1 as the substrate. The autoradiography of ³²P incorporation is shown at the top. The ³²P intensities of each mutant normalized against WT Mst2^{KD} (100%) were quantified and are indicated below the autoradiography. The Coomassie blue staining of Mob1 was shown in the lower panel.

See also Figure S3 and Table S1.

Because our mutations targeted residues close to the active site, we tested the ability of these mutants to phosphorylate the kinase-inactive Mst2^{KD/D146N} or its downstream substrate Mob1. Based on both ³²P incorporation and anti-Mst2 pT180 blot, two mutations, I193A and F231A, severely inhibited Mst2 autophosphorylation at T180 (Figure 3C). Whereas the F231A mutant was also defective in Mob1 phosphorylation, the I193A mutant was fully functional in Mob1 phosphorylation (Figure 3D). On the other hand, the M227A/I230A mutant was capable of undergoing autophosphorylation at T180 but was inactive toward Mob1. Therefore, Mst2 appears to use overlapping but distinct surfaces to perform transautophosphorylation or phosphorylation of other substrates. I193 is specifically involved in autophosphorylation. We note that the I193A mutant purified from bacteria still underwent autophosphorylation at T180, indicating that this residue is not absolutely required for Mst2 autoactivation.

Of note, the I193A mutation inhibited Mst2 autophosphorylation at T180, even in the context of the full-length Mst2 (Figure 4A). Furthermore, ectopic expression of Flag-Mst2 wild-type (WT), but not the I193A and F231A mutants, enhanced

the phosphorylation of HA-YAP and Myc-Lats1/2 in human cells (Figures 4B and 4C), indicating that I193 was required for Mst2 activity and function in vivo.

The underlying reason for why Mst2 I193A undergoes autophosphorylation in bacteria, but not in human cells, is unclear at present, but this difference could be due to the presence of phosphatases in human cells. A similar mutation in the Hippo kinase domain has been shown to impair Hippo autophosphorylation and activation in *Drosophila*, suggesting that the activation mechanism of Mst1/2 is conserved (Jin et al., 2012). Finally, our results indicate that SARA-mediated dimerization of Mst2 is critical for Mst2 autophosphorylation and activation. Even though the Mst2 kinase domain in isolation forms a weak dimer, there is no evidence supporting the importance of this dimerization in Mst2 activation.

Structure of the Mst2-RASSF5 Complex

We failed to obtain crystals of full-length Mst1/2. We thus analyzed the overall structural architecture of Mst2 by nuclear magnetic resonance (NMR) spectroscopy. Due to the large




Figure 4. Mst2 Autoactivation Is Required for Lats1/2 and YAP Phosphorylation in Human Cells

(A) I193A inhibits Mst2 autophosphorylation at T180, even in the context of the full-length Mst2. The kinetics profiles of T180 autophosphorylation of full-length Mst2 (at 0.5 μ M), full-length point mutant Mst2^{I193A} (at 0.5 μ M), and Mst2^{KD/I193A} (at 2 μ M and 0.5 μ M) are shown on the left. An enlarged view of the boxed region in the left graph is shown on the right. The full-length Mst2^{I193A} was slightly more efficient than Mst2^{KD/I193A} in autophosphorylation. Data are representative of at least two independent experiments.

(B) Overexpression of Flag-Mst2 WT, but not the I193A and F231A mutants, enhanced the phosphorylation of HA-YAP. Anti-HA immunoprecipitation (IP) from HEK293 cells expressing the indicated constructs was probed with α -phospho-YAP and α -YAP (HA). A fraction of the cell lysate was probed with α -Mst2 (Flag) to evaluate protein expression levels.

(C) Overexpression of Flag-Mst2 WT, but not the I193A and F231A mutants, enhanced the

phosphorylation of Myc-Lats1 (left) and Myc-Lats2 (right). Myc-IP from HEK293 cells expressing the indicated constructs was probed with α -phospho-Wts and α -Myc. A fraction of the cell lysate was probed with α -Mst2 (Flag) to evaluate protein expression levels.

See also Figure S4.

molecular weight of Mst2, the transverse relaxation optimized spectroscopy (TROSY) version of heteronuclear single-quantum correlation (HSQC) experiments was performed (Pervushin, 2000). The ¹H/¹⁵N TROSY-HSQC spectrum of Mst2 contained many sharp peaks between 7.5 and 8.5 parts per million (ppm) in the ¹H dimension, indicating that many residues of Mst2 were disordered (Figure S4A). By contrast, the ¹H/¹⁵N TROSY-HSQC spectrum of the Mst2 mutant with its linker between the kinase and SARAH domains deleted (Mst2^{ΔL}) had few sharp peaks, indicating that the Mst2 linker was natively unfolded (Figure S4B). Therefore, Mst2 existed as a homodimer with two juxtaposed kinase-domain heads and a SARAH coiled-coil domain connected by flexible linkers (Figure S4C). Mst2^{ΔL} was fully functional and capable of autophosphorylation (Figure S4D). Similar to Mst2^{WT}, Mst2^{ΔL} formed a 1:1 heterodimer with RASSF5 on a gel filtration column (Figures S5A and S5B). We thus used Mst2^{ΔL} in subsequent structural studies.

We determined the structure of kinase-dead Mst2^{ΔL/D146N} bound to AMP-PNP and the SARAH domain of RASSF5, which we refer to as Mst2-RASSF5 hereinafter for simplicity. Mst2-RASSF5 again formed a dimer in crystal through the Mst2 kinase domain (Figure 5A). It is intriguing that, although the dimer interface of the Mst2 kinase domains also mainly involves α G, the relative orientation of the two kinase domains and their specific contacts are different from those observed in the active Mst1^{KD} (Figure S5C) or inactive Mst2^{KD} structures, suggesting that the dimer interfaces of Mst1/2 kinase heads in crystals might not be specific.

The active site of Mst2-RASSF5 is well defined, as the Mg²⁺ ion and AMP-PNP are clearly visible in the electron density map. The kinase domain in Mst2-RASSF5 is very similar to the Mst2 kinase alone, except that the activation-loop helix observed in the Mst2 kinase structure has partially melted in

the Mst2-RASSF5 structure (Figure S5D). The K56–E70 salt bridge between strand β 3 and helix α C is also not formed in the Mst2-RASSF5 structure. The residual linker between the kinase domain and SARAH domain is invisible and, presumably, disordered. The SARAH domains of Mst2 and RASSF5 form a long antiparallel coiled coil. Because the SARAH domains of Mst1 and Mst2 share 70% sequence identity (Figure 5B), they most likely share the same fold. The solution structure of the Mst1 SARAH homodimer has been previously determined (Figure 5C) (Hwang et al., 2007). The surfaces of Mst1/2 SARAH for binding to RASSF5 SARAH (heterodimerization) or to another Mst1/2 SARAH (homodimerization) are virtually identical (Figures 5C and 5D), readily explaining the disruption of SARAH-mediated Mst2 homodimerization by RASSF5 binding (Figure 5E).

Structural Determinants of Mst2 SARAH Homodimerization and Mst2-RASSF5 SARAH Heterodimerization

Addition of purified RASSF5 to the full-length Mst2 abolished its autophosphorylation and activation in vitro (Figure 6A). To test whether RASSF5 blocked Mst2 activation through disrupting Mst2 homodimerization, we sought to obtain Mst2 mutants that retained homodimerization but lost their ability to heterodimerize with RASSF5. Based on the Mst1 SARAH homodimer structure, we designed the point mutations of all conserved interface residues in the Mst2 SARAH domain (Figures 5B–5D). We systematically mutated these interface residues in the context of the full-length Mst2 and tested their dimerization in an in vitro binding assay (Figures 6B and 6C). Briefly, we cotranslated HA- or Myc-Mst2 in rabbit reticulocyte lysate in the presence of ³⁵S-methionine and performed immunoprecipitation with anti-HA beads. The WT HA-Mst2 efficiently pulled down




Figure 5. Structure of the Mst2-RASSF5 Complex

(A) Ribbon diagram of the crystallographic dimer of the Mst2-RASSF5 complex. In monomer A, Mst2 is colored green, RASSF5 is colored orange, and the activation loop is colored magenta. In monomer B, Mst2 is colored gray, RASSF5 is colored sand, and the activation loop is colored wheat. AMP-PNP is shown in sticks, and Mg^{2+} is shown as a gray sphere.

(B) Sequence alignment of SARAH domains from Mst1/2 and RASSF proteins. The sequence alignment of Mst1 and Mst2 SARAH domains is shown at the top, with identical residues colored red and the conserved interface residues marked by asterisks. The secondary structure elements are shown above the sequences and colored green. The sequence alignment of RASSF SARAH domains is shown at the bottom. h, *Homo sapiens*; m, mouse; d, *Drosophila*; x, *Xenopus*; c, *C. elegans*. The conserved residues are shaded in yellow. W369 and F372 in the H1 helix are marked by asterisks. The secondary structure elements are shown above the sequences and colored orange.

(C) The solution structure of Mst1 SARAH homodimer. Protomer A is colored green, and the conserved Mst1 interface residues are shown in sticks and labeled. Protomer B is colored light green.

(D) The crystal structure of Mst2-RASSF5 SARAH heterodimer. The same color scheme as in (A) was used. The conserved interface residues are shown in sticks, and residues from Mst2 are labeled. The homodimerization-defective mutants are labeled in magenta, and K473 is indicated in red.

(E) A schematic drawing of the SARAH domain exchange between the Mst2 homodimer and Mst2-RASSF5 heterodimer.

See also Figure S5.

Myc-Mst2, confirming that Mst2 indeed formed dimers. Among the 14 mutants, Mst2 L448A, L452A, L455A, E462A, I463A, Y470A, and L478A displayed minimal dimerization (Figure 6C), indicating that the SARAH domain of Mst2 was the major dimerization interface. The weak dimerization of the Mst2 kinase domain was not detectable by this assay.

Compared to the WT Mst2, HA-Mst2 L445A, D456A, L466A, R467A, R469A, K473A, and R474A still retained at least 30% binding to their Myc-tagged counterparts, (Figures 6B and 6C). We thus tested the binding of these ^{35}S -labeled Mst2 mutants to glutathione S-transferase (GST)-RASSF5 SARAH. As expected, Mst2 WT bound specifically to GST-RASSF5-SARAH but not to GST (Figures 6D and 6E). Six of the seven Mst2 mutants had stronger binding to RASSF5, presumably because these mutations disrupted the Mst2 homodimerization more severely than they disrupted Mst2-RASSF5 heterodimerization. Only Mst2 K473A exhibited reduced RASSF5 binding, as

compared to Mst2 WT. Mst2 K473A still underwent efficient autophosphorylation and activation, which were not effectively blocked by RASSF5 (Figure 6A). This result confirms that RASSF5 blocks Mst2 activation through disrupting SARAH-mediated Mst2 homodimerization.

Functions of RASSFs in Mst1/2 Regulation

If RASSF5 simply prevents Mst2 autophosphorylation and activation, then binding of RASSF5 to the already fully activated Mst2 kinase should have no effect on the kinase activity. Indeed, in the presence of RASSF5, the activated Mst2 phosphorylated either Mob1 or myelin basic protein (MBP) in a manner similar to that of Mst2 alone (Figures 7A and 7B). Therefore, RASSF5 does not inhibit the already activated Mst2 kinase.

Collectively, our results support the following model for Mst1/2 regulation by RASSFs (Figure 7C). When the Hippo pathway is




Figure 6. RASSF5 Blocks Mst2 Autoactivation through Heterodimerization

(A) The kinetic profiles of T180 autophosphorylation of full-length Mst2, the full-length Mst2 and RASSF5-SARAH complex, the full-length point mutant Mst2^{K473A}, and the full-length point mutant Mst2^{K473A} and RASSF5-SARAH complex are shown. The relative α -Mst2 P-T180 intensities were normalized against Mst2 reaction at 60 min (100%). Data are representative of at least two independent experiments.

(B) In vitro dimerization assay of Mst2 mutants. HA- and Myc-tagged Mst2 proteins were cotranslated in vitro in the presence of ³⁵S-methionine. The input (top) and anti-HA IP (bottom) were separated by SDS-PAGE and analyzed with a phosphor imager. Mutants that retain the dimerization ability were colored blue.

(C) Quantification of the homodimerization of Mst2 mutants in (B).

(D) Binding between GST-RASSF5-SARAH and in-vitro-translated Mst2 proteins. Mst2^{K473A} has a weakened interaction with GST-RASSF5 and is labeled in red.

(E) Quantification of GST-RASSF5 binding of Mst2 mutants in (D).

off, RASSFs form heterodimers with Mst1/2 through heterotypic SARAH interactions, thus blocking the homodimerization and transautophosphorylation of Mst1/2. In this context, RASSFs act as inhibitors of apoptosis. When the Hippo pathway is on, Mst1/2 undergoes homodimerization and autoactivation, possibly through Sav1-dependent displacement of RASSFs. RASSFs can then bind to already activated Mst1/2. This binding does not inhibit the kinase activity of Mst1/2 but may instead promote the function of Mst1/2 through unknown mechanisms. In this capacity, RASSFs act as activators of apoptosis and tumor suppressors. Thus, RASSFs are double-edged swords in the Hippo pathway. Depending on the timing of their binding to Mst1/2 relative to Mst1/2 autophosphorylation, RASSFs can either function as inhibitors or activators of Mst1/2 and the Hippo pathway.

Conclusions

The Hippo pathway is a major regulatory pathway of cell proliferation and survival. Dysregulation of the Hippo pathway is intimately linked to cancer. Our study provides key structural and mechanistic insights into the activation of Mst1/2, the upstream kinases in this pathway. In particular, we have revealed important roles of RASSFs in regulating Mst1/2 in vitro. Binding of RASSFs to unphosphorylated, inactive Mst1/2 blocks their autoactivation. Binding of RASSFs to the already activated Mst1/2 does not inhibit their kinase activities but may simulate Mst1/2 function through other mechanisms. Our study provides a potential explanation for the perplexing dual functions of RASSFs in vivo. By virtue of their ability to interact with both Mst1/2 and Ras proteins, RASSFs are at the intersection of the Hippo and Ras pathways. Temporal regulation of the




Figure 7. RASSF5 Does Not Inhibit the Kinase Activity of Mst2 that Has Already Undergone Autoactivation

(A) The kinetic profiles of Mob1 phosphorylation by the full-length Mst2 and the Mst2-RASSF5 complex containing already activated Mst2, as monitored by ^{32}P incorporation.

(B) The kinetic profiles of MBP phosphorylation by activated full-length Mst2, and by the Mst2-RASSF5 complex, as monitored by ^{32}P incorporation. Data are representative of four independent experiments.

(C) Model for the dual modes of Mst2 regulation by RASSF5.

Crystallization, Data Collection, and Structure Determination

Mst2^{KD/D146N} was crystallized at 4°C using the hanging-drop vapor diffusion method with a reservoir solution containing 0.2 M sodium citrate, 15% (w/v) polyethylene glycol (PEG) 3350, and 0.1 M HEPES (pH 7.7). The crystals were cryo-protected with the reservoir solution supplemented with 25% (v/v) glycerol and then flash cooled in liquid nitrogen. Crystals diffracted to a minimum Bragg spacing (d_{\min}) of 2.42 Å and exhibited the symmetry of space group C2, with cell dimensions of $a = 227.2$ Å, $b = 69.8$ Å, $c = 148.1$ Å, and $\beta = 108.6^\circ$ and contained six Mst2^{KD/D146N} molecules per asymmetric unit.

Mst2^{ΔL/D146N}-RASSF5^{SARAH} was crystallized at 20°C using the hanging-drop vapor diffusion method with a reservoir solution containing 0.1 M Bis-Tris propane (pH 8.5), 200 mM Na₂SO₄, and 20% (w/v) PEG 3350. The crystals were cryo-protected with the reservoir solution supplemented with 25% glycerol and then flash cooled in liquid nitrogen. Native crystals diffracted to a minimum Bragg spacing (d_{\min}) of 3.05 Å and exhibited the symmetry of space group C2, with cell dimensions of $a = 123.4$ Å, $b = 237.1$ Å, $c = 95.9$ Å, and $\beta = 100.7^\circ$ and contained four Mst2-RASSF5 heterodimers per asymmetric unit. The selenomethionine-derivatized Mst2^{ΔL/D146N}-RASSF5^{SARAH} crystals were obtained in the same way and had similar cell parameters. The selenomethionine-derivatized crystals only diffracted to a minimum Bragg spacing of 3.55 Å. All crystals showed significant anisotropic diffraction. Single-wavelength anomalous dispersion (SAD) data on the selenomethionine Mst2^{ΔL/D146N}-RASSF5^{SARAH} crystals were collected at 3.55 Å, with weak anomalous signal present to about 5 Å.

All diffraction data were collected at beamline 19-ID (SBC-CAT) at the Advanced Photon Source (Argonne National Laboratory, Argonne, IL, USA) and processed with HKL3000 (Otwinowski and Minor, 1997). Phases for Mst2^{KD/D146N} were obtained by MR with Phaser using the crystal structure of human Mst1 kinase domain (PDB code: 3COM) as the search model (McCoy et al., 2007). Iterative model building and refinement were performed with COOT and Phenix, respectively (Adams et al., 2010; Emsley and Cowtan, 2004). The final model for Mst2^{KD/D146N} ($R_{\text{work}} = 19.3\%$, $R_{\text{free}} = 23.1\%$) contained 1,646 residues in six monomers, 279 water molecules, and four glycerols. Two residues, L33 and D164, are outliers in the Ramachandran plot as defined in the program MolProbity (Davis et al., 2007). Both are located in surface loops with poor electron density.

Phases for Mst2^{ΔL/D146N}-RASSF5^{SARAH} were first obtained by MR with Phaser using Mst2^{KD/D146N} structure as the search model. Phenix was used to build and refine a partial model only containing the Mst2 kinase domain. The resulting electron density map clearly showed several helices from the SARAH domains, yet the primary sequence for these helices was impossible to assign due to poor side chain density, and the density for the RASSF5^{SARAH} helices was weak and disconnected. The MR-SAD module of Phaser was used to calculate initial phases to 3.6 Å from the MR solution and the known 36 selenium sites in the Mst2^{ΔL/D146N} kinase domains from a selenium-SAD experiment, and to locate the remaining 16 selenium sites in the SARAH

binding between Mst1/2 and RASSFs affords an opportunity for the Hippo pathway to respond to and integrate diverse cellular signals.

EXPERIMENTAL PROCEDURES

Plasmids, Protein Expression, and Purification

The kinase domain of human Mst2 (Mst2^{KD}, residues 16–313) was cloned into a modified pET28 vector (EMD Millipore) that included a tobacco etch virus (TEV) cleavage site at the N terminus. The full-length Mst2 (Mst2^{FL}, residues 9–491) and linker-deletion Mst2 (Mst2^{ΔL}, residues 9–313 and 428–491) were cloned into a modified pET29 vector (EMD Millipore) that included an N-terminal His₆ tag without a protease cleavage site. The C-terminal domain of Mst2 (Mst2^{CTD}, residues 314–491) and the SARAH domain of human RASSF5 (RASSF5^{SARAH}, residues 366–413) were cloned into a modified pGEX-6P vector (GE Healthcare) that included a TEV cleavage site at their N termini. The Mst2 mutants were generated with the QuikChange mutagenesis kit (Stratagene). All constructs were verified by DNA sequencing.

When expressed alone in bacteria, the yield of Mst2 was extremely low. To obtain large quantities of soluble Mst2 proteins, we cotransformed the pET28-Mst2^{KD}, pET29-Mst2^{FL}, or pET29-Mst2^{ΔL} plasmid into BL21(DE3) with pGEX-6p-Mst2^{CTD} to produce N-terminal His₆-tagged Mst2 proteins. Mst2^{KD} was purified with Ni²⁺-NTA agarose resin (QIAGEN) and cleaved with TEV to remove the His₆ tag. His₆-Mst2^{FL} and His₆-Mst2^{ΔL} were purified with Ni²⁺-NTA agarose resin. These proteins were further purified by a Resource Q anion exchange column and followed by a Superdex 200 gel filtration column (GE Healthcare). Purified Mst2 proteins were concentrated to 20 mg/ml in a buffer containing 20 mM Tris (pH 7.7), 100 mM NaCl, 2 mM MgCl₂, and 5 mM TCEP.

The Mst2^{ΔL/D146N}-RASSF5^{SARAH} complex was obtained by coexpression of pET29-Mst2^{ΔL/D146N} and pGEX-6p-RASSF5^{SARAH} in the *E. coli* strain BL21(DE3). Mst2^{ΔL/D146N}-RASSF5^{SARAH} was purified with Glutathione Sepharose 4B beads (GE Healthcare) and cleaved with TEV to remove the GST moiety. Mst2^{ΔL/D146N}-RASSF5^{SARAH} was further purified by a Superdex 200 gel filtration column and then concentrated to 10 mg/ml in a buffer containing 20 mM Tris (pH 7.7), 100 mM NaCl, 2 mM MgCl₂ and 5 mM TCEP. The selenomethionine-labeled Mst2^{ΔL/D146N}-RASSF5^{SARAH} was produced using the methionine biosynthesis inhibition method (Van Duyne et al., 1993).

domains of Mst2^{ΔL/D146N}. Iterative cycles of solvent flattening and 4-fold averaging in Parrot, automatic model building in Buccaneer, and phase calculation and refinement in the MR-SAD module of Phaser resulted in a model with 1,483 residues (89%) built and assigned (Winn et al., 2011). The side chain assignment of RASSF5^{SARAH} was further confirmed by packing interactions with the Mst2^{ΔL/D146N} SARAH domain. Completion of the model and final refinement was performed using the native data to 3.05 Å. The final model for Mst2^{ΔL/D146N}-RASSF5^{SARAH} ($R_{\text{work}} = 19.9\%$, $R_{\text{free}} = 24.4\%$) contained 1,551 residues in four monomers, four molecules of Mg²⁺-AMP-PNP, three sodium ions, and nine sulfate ions. Three residues, E31, T174, and E311, are outliers in the Ramachandran plot, as defined in the program MolProbity, and are located in surface loops with weak electron density. Data collection and structure refinement statistics are summarized in Table 1.

Analytical Ultracentrifugation

All sedimentation velocity analytical ultracentrifugation experiments were performed in an An-50Ti rotor at 20°C using a Beckman-Coulter Optima XL-I analytical ultracentrifuge. Protein samples (400 μl) in the gel filtration buffer (20 mM Tris, pH 7.7, 100 mM NaCl, 2 mM MgCl₂, 1 mM TCEP) at three different concentrations in the range of 2–100 μM were placed in one sector of centrifugation cells that housed dual-sector charcoal-filled Epon centerpieces. The same volumes of the gel filtration buffer were placed in the other sector of centerpieces as reference. The sealed centrifugation cells and the rotor were incubated at the experimental temperature under vacuum for at least 2 hr prior to centrifugation. Samples were centrifuged at 50,000 rpm until the boundary region reached the bottom of cells. Concentration profiles of the proteins were monitored using the on-board absorption optical system tuned to 280 nm and, where appropriate, the Rayleigh interferometer. The partial specific volume (0.7421 ml/g) based on the amino acid sequence, the solution density (1.00309 g/ml), and the viscosity (0.010177 P) of the buffer was calculated using SEDNTERP (Laue et al., 1992). Data were directly fitted and optimized to the monomer-dimer self-association model with the Marquadt-Levenberg methods using the Lamm equation with explicit reaction kinetics in SEDPHAT (<http://www.analyticalultracentrifugation.com>) (Brautigam, 2011; Schuck, 2003). A global analysis was performed for data sets obtained at different protein concentrations to calculate the dissociation constant for each protein sample.

NMR Spectroscopy

All NMR spectra were acquired at 30°C on a Varian INOVA 600 MHz four-channel spectrometer equipped with a pulsed-field gradient triple resonance probe using H₂O/D₂O 95:5 (v/v) as the solvent. Samples typically contained 0.1 mM ¹⁵N-labeled protein in the NMR buffer consisting of 20 mM sodium phosphate (pH 6.8), 100 mM KCl, 2 mM MgCl₂, and 1 mM dithiothreitol (DTT). The data were processed and analyzed with NMRPipe and NMRView (Delaglio et al., 1995; Johnson and Blevins, 1994).

In Vitro Kinase Assays and Autophosphorylation

For in vitro kinase assays, 0.025–0.4 μM Mst2 kinase or its mutants, either alone or in complex with RASSF5, was incubated in the kinase buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 10 mM MgCl₂, 1 mM ATP, 1 mM DTT, and 0.1 μCi/μl γ-³²P-ATP with 40 μM substrate (Mob1, or Mst2^{KD/D146N}, or MBP) for 30 min at room temperature. The reaction was terminated by adding 5× SDS sample buffer and followed by boiling for 5 min in 100°C water bath. The mixture was separated by SDS-PAGE and analyzed by autoradiography.

For autophosphorylation experiments, the WT Mst2 protein purified from *E. coli* was treated with lambda (λ) protein phosphatase (New England Biolabs) at 30°C for 40 min to remove the phosphorylation at T180. The reaction was stopped by adding phosphatase inhibitor Na₃VO₄ to a final concentration of 3 mM. The treated Mst2 was then incubated at room temperature in the kinase buffer containing 50 mM Tris (pH 7.5), 150 mM NaCl, 10 mM MgCl₂, 1 mM ATP, 1 mM DTT, and 1 mM Na₃VO₄. At the indicated time intervals, aliquots were removed and mixed with 5× SDS sample buffer. The autophosphorylation product was detected by western blot using a specific antibody against phospho-T180 of Mst2 (Cell Signaling) and quantified with the Odyssey LI-COR imaging system.

Cell Culture and Transfection

HEK293 cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum. Plasmid transfections were performed with the Effectene reagent (QIAGEN) according to manufacturer's instructions. HA-YAP, Flag-Mst2, Myc-Lats1, and Myc-Lats2 have been described elsewhere (Dong et al., 2007). Flag-Mst2^{T193A} and Flag-Mst2^{F231A} were made using the QuikChange mutagenesis kit (Stratagene). All clones were verified by DNA sequencing. Immunoprecipitation was performed as described elsewhere (Yu et al., 2010). The western blots were developed using the Amersham ECL chemi-luminescence system (GE Healthcare).

In Vitro Binding Assays

To assay Mst2 homodimerization, same amounts of plasmids encoding Myc- or HA-tagged Mst2 WT or point mutants were translated in reticulocyte lysate in the presence of ³⁵S-methionine. Affi-Prep protein A beads (Bio-Rad) covalently coupled to α-HA monoclonal antibodies (Roche) were incubated with ³⁵S-labeled Mst2 and washed three times with Tris-buffered saline (TBS) containing 0.05% Tween. The bound proteins were separated by SDS-PAGE and analyzed with a phosphor imager (Fujifilm).

To assay the binding between human Mst2 and RASSF5 proteins, the full-length WT or point mutants of Mst2 were translated in reticulocyte lysate in the presence of ³⁵S-methionine. Purified GST-RASSF5^{SARAH} was bound to glutathione-agarose beads (GE Healthcare), incubated with ³⁵S-labeled Mst2 proteins, and washed three times with TBS containing 0.05% Tween. The proteins retained on the beads were analyzed by SDS-PAGE followed by autoradiography. Glutathione-agarose beads bound to GST were used as controls.

ACCESSION NUMBERS

The atomic coordinates and structure factors for human Mst2 kinase domain and Mst2-RASSF5 have been deposited in the PDB with the ID codes 4LGD and 4LGD, respectively.

SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and one table and can be found with this article online at <http://dx.doi.org/10.1016/j.str.2013.07.008>.

ACKNOWLEDGMENTS

We thank Hongtao Yu for discussion and critical reading of the manuscript. We also thank Boning Gao for providing the RASSF5 plasmid. Results shown in this study are derived from work performed at Argonne National Laboratory, Structural Biology Center at the Advanced Photon Source. The Argonne National Laboratory is operated by the University of Chicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research, under contract DE-AC02-06CH11357. This work was supported in part by grants from the National Institutes of Health (GM085004 to X.L. and EY015708 to D.P.). J.Y. is a recipient of a Young Investigator Award from the Children's Tumor Foundation. D.P. is an investigator of the Howard Hughes Medical Institute.

Received: June 4, 2013

Revised: July 12, 2013

Accepted: July 16, 2013

Published: August 22, 2013

REFERENCES

- Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* 66, 213–221.
- Aoyama, Y., Avruch, J., and Zhang, X.F. (2004). Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. *Oncogene* 23, 3426–3433.

- Avruch, J., Xavier, R., Bardeesy, N., Zhang, X.F., Praskova, M., Zhou, D., and Xia, F. (2009). Rassf family of tumor suppressor polypeptides. *J. Biol. Chem.* 284, 11001–11005.
- Avruch, J., Zhou, D., Fitamant, J., Bardeesy, N., Mou, F., and Barrufet, L.R. (2012). Protein kinases of the Hippo pathway: regulation and substrates. *Semin. Cell Dev. Biol.* 23, 770–784.
- Badouel, C., Garg, A., and McNeill, H. (2009). Herding Hippos: regulating growth in flies and man. *Curr. Opin. Cell Biol.* 21, 837–843.
- Brautigam, C.A. (2011). Using Lamm-Equation modeling of sedimentation velocity data to determine the kinetic and thermodynamic properties of macromolecular interactions. *Methods* 54, 4–15.
- Cooper, W.N., Hesson, L.B., Matallanas, D., Dallol, A., von Kriegsheim, A., Ward, R., Kolch, W., and Latif, F. (2009). RASSF2 associates with and stabilizes the proapoptotic kinase MST2. *Oncogene* 28, 2988–2998.
- Creasy, C.L., Ambrose, D.M., and Chernoff, J. (1996). The Ste20-like protein kinase, Mst1, dimerizes and contains an inhibitory domain. *J. Biol. Chem.* 271, 21049–21053.
- Davis, I.W., Leaver-Fay, A., Chen, V.B., Block, J.N., Kapral, G.J., Wang, X., Murray, L.W., Arendall, W.B., 3rd, Snoeyink, J., Richardson, J.S., and Richardson, D.C. (2007). MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res.* 35(Web Server issue), W375–W383.
- Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J., and Bax, A. (1995). NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* 6, 277–293.
- Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S.A., Gayyed, M.F., Anders, R.A., Maitra, A., and Pan, D. (2007). Elucidation of a universal size-control mechanism in *Drosophila* and mammals. *Cell* 130, 1120–1133.
- Edgar, B.A. (2006). From cell structure to transcription: Hippo forges a new path. *Cell* 124, 267–273.
- Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* 60, 2126–2132.
- Guo, C., Tommasi, S., Liu, L., Yee, J.K., Dammann, R., and Pfeifer, G.P. (2007). RASSF1A is part of a complex similar to the *Drosophila* Hippo/Salvador/Lats tumor-suppressor network. *Curr. Biol.* 17, 700–705.
- Halder, G., and Johnson, R.L. (2011). Hippo signaling: growth control and beyond. *Development* 138, 9–22.
- Hao, Y., Chun, A., Cheung, K., Rashidi, B., and Yang, X. (2008). Tumor suppressor LATS1 is a negative regulator of oncogene YAP. *J. Biol. Chem.* 283, 5496–5509.
- Harvey, K., and Tapon, N. (2007). The Salvador-Warts-Hippo pathway—an emerging tumour-suppressor network. *Nat. Rev. Cancer* 7, 182–191.
- Harvey, K.F., Zhang, X., and Thomas, D.M. (2013). The Hippo pathway and human cancer. *Nat. Rev. Cancer* 13, 246–257.
- Hergovich, A. (2012). Mammalian Hippo signalling: a kinase network regulated by protein-protein interactions. *Biochem. Soc. Trans.* 40, 124–128.
- Hong, W., and Guan, K.L. (2012). The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. *Semin. Cell Dev. Biol.* 23, 785–793.
- Huang, J., Wu, S., Barrera, J., Matthews, K., and Pan, D. (2005). The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the *Drosophila* Homolog of YAP. *Cell* 122, 421–434.
- Hwang, E., Ryu, K.S., Pääkkönen, K., Güntert, P., Cheong, H.K., Lim, D.S., Lee, J.O., Jeon, Y.H., and Cheong, C. (2007). Structural insight into dimeric interaction of the SARAH domains from Mst1 and RASSF family proteins in the apoptosis pathway. *Proc. Natl. Acad. Sci. USA* 104, 9236–9241.
- Ikeda, M., Kawata, A., Nishikawa, M., Tateishi, Y., Yamaguchi, M., Nakagawa, K., Hirabayashi, S., Bao, Y., Hidaka, S., Hirata, Y., and Hata, Y. (2009). Hippo pathway-dependent and -independent roles of RASSF6. *Sci. Signal.* 2, ra59.
- Jin, Y., Dong, L., Lu, Y., Wu, W., Hao, Q., Zhou, Z., Jiang, J., Zhao, Y., and Zhang, L. (2012). Dimerization and cytoplasmic localization regulate Hippo kinase signaling activity in organ size control. *J. Biol. Chem.* 287, 5784–5796.
- Johnson, B.A., and Blevins, R.A. (1994). NMR View: A computer program for the visualization and analysis of NMR data. *J. Biomol. NMR* 4, 603–614.
- Khokhlatchev, A., Rabizadeh, S., Xavier, R., Nedwiedek, M., Chen, T., Zhang, X.F., Seed, B., and Avruch, J. (2002). Identification of a novel Ras-regulated proapoptotic pathway. *Curr. Biol.* 12, 253–265.
- Laue, T.M., Shah, B., Ridgeway, R., and Pelletier, S.L. (1992). Computer-aided interpretation of analytical sedimentation data for proteins (Cambridge, UK: The Royal Society of Chemistry).
- Luo, X. (2010). Snapshots of a hybrid transcription factor in the Hippo pathway. *Protein Cell* 1, 811–819.
- Matallanas, D., Romano, D., Yee, K., Meissl, K., Kucerova, L., Piazzolla, D., Baccarini, M., Vass, J.K., Kolch, W., and O'Neill, E. (2007). RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. *Mol. Cell* 27, 962–975.
- McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. *J. Appl. Crystallogr.* 40, 658–674.
- Oh, H.J., Lee, K.K., Song, S.J., Jin, M.S., Song, M.S., Lee, J.H., Im, C.R., Lee, J.O., Yonehara, S., and Lim, D.S. (2006). Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. *Cancer Res.* 66, 2562–2569.
- Otwinski, Z., and Minor, W. (1997). Processing X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* 276, 307–326.
- Pan, D. (2010). The hippo signaling pathway in development and cancer. *Dev. Cell* 19, 491–505.
- Pervushin, K. (2000). Impact of transverse relaxation optimized spectroscopy (TROSY) on NMR as a technique in structural biology. *Q. Rev. Biophys.* 33, 161–197.
- Pirruccello, M., Sondermann, H., Pelton, J.G., Pellicena, P., Hoelz, A., Chernoff, J., Wemmer, D.E., and Kuriyan, J. (2006). A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases. *J. Mol. Biol.* 361, 312–326.
- Polesello, C., Huelsmann, S., Brown, N.H., and Tapon, N. (2006). The *Drosophila* RASSF homolog antagonizes the hippo pathway. *Curr. Biol.* 16, 2459–2465.
- Praskova, M., Khokhlatchev, A., Ortiz-Vega, S., and Avruch, J. (2004). Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. *Biochem. J.* 381, 453–462.
- Richter, A.M., Pfeifer, G.P., and Dammann, R.H. (2009). The RASSF proteins in cancer: from epigenetic silencing to functional characterization. *Biochim. Biophys. Acta* 1796, 114–128.
- Schuck, P. (2003). On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation. *Anal. Biochem.* 320, 104–124.
- Song, H., Oh, S., Oh, H.J., and Lim, D.S. (2010). Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. *Biochem. Biophys. Res. Commun.* 391, 969–973.
- Staley, B.K., and Irvine, K.D. (2012). Hippo signaling in *Drosophila*: recent advances and insights. *Dev. Dyn.* 241, 3–15.
- Sudol, M., Shields, D.C., and Farooq, A. (2012). Structures of YAP protein domains reveal promising targets for development of new cancer drugs. *Semin. Cell Dev. Biol.* 23, 827–833.
- Tommasi, S., Dammann, R., Zhang, Z., Wang, Y., Liu, L., Tsark, W.M., Wilczynski, S.P., Li, J., You, M., and Pfeifer, G.P. (2005). Tumor susceptibility of RASSF1a knockout mice. *Cancer Res.* 65, 92–98.
- Van Duyne, G.D., Standaert, R.F., Karplus, P.A., Schreiber, S.L., and Clardy, J. (1993). Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. *J. Mol. Biol.* 229, 105–124.
- Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., et al. (2011).

Overview of the CCP4 suite and current developments. *Acta Crystallogr. D Biol. Crystallogr.* 67, 235–242.

Yu, J., Zheng, Y., Dong, J., Klusza, S., Deng, W.M., and Pan, D. (2010). Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. *Dev. Cell* 18, 288–299.

Zhao, B., Wei, X., Li, W., Udan, R.S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007). Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev.* 21, 2747–2761.

Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J.D., Wang, C.Y., Chinnaiyan, A.M., et al. (2008). TEAD mediates YAP-dependent gene induction and growth control. *Genes Dev.* 22, 1962–1971.

Zhao, B., Li, L., Lei, Q., and Guan, K.L. (2010a). The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. *Genes Dev.* 24, 862–874.

Zhao, B., Li, L., Tumaneng, K., Wang, C.Y., and Guan, K.L. (2010b). A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). *Genes Dev.* 24, 72–85.